Vall D'hebron University
Neoadjuvant immune checkpoint inhibitor therapy improves outcomes in early breast cancer
The addition of immune checkpoint inhibitor therapy to neoadjuvant chemotherapy improved pathologic complete response and EFS for certain patients with early-stage breast cancer, according to a systematic review and meta-analysis.
Combination yields ‘promising PFS outcomes’ in certain patients with breast cancer
SAN ANTONIO — The combination of zanidatamab, palbociclib and fulvestrant yielded promising PFS results among adults with HER2-positive/hormone receptor-positive metastatic breast cancer, findings from a phase 2A study showed.
Atezolizumab-bevacizumab combo extends survival among certain women with cervical cancer
The addition of atezolizumab to bevacizumab and first-line chemotherapy improved PFS and OS compared with standard chemotherapy alone among women with metastatic, persistent or recurrent cervical cancer, study results showed.
Camizestrant extends PFS for postmenopausal women with advanced breast cancer
SAN ANTONIO — Camizestrant significantly prolonged PFS compared with fulvestrant among postmenopausal women with advanced ER-positive, HER2-negative breast cancer, according to study results.